Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria.
BACKGROUND
Previously the angiotensin II receptor blocker Irbesartan has been demonstrated to reduce the risk for progression from microalbuminuria to macroalbuminuria in type 2 diabetic patients. The purpose of this study was to evaluate the effect of treatment with Irbesartan in type 2 diabetic patients with microalbuminuria on the urinary proteome.


METHODS
High-resolution capillary-electrophoresis coupled to mass-spectrometry (CE-MS) was used to profile the low-molecular-weight proteome in urine of a subgroup of patients from a two year randomized irbesartan versus placebo therapy trial, which included hypertensive type 2 diabetic patients with microalbuminuria on ongoing antihypertensive medication (IRMA2-substudy).


RESULTS
We demonstrate that the therapy with 300 mg Irbesartan daily over a period of two years results in significant changes of the urinary proteome. Both, a classifier developed previously that consists of urinary peptides indicative of chronic kidney disease, as well as several individual peptides changed significantly after treatment. These changes were not observed in the placebo-treated individuals. Most prominent are changes of urinary collagen fragments associated with progression of diabetic nephropathy, indicating normalization in urinary peptides.


CONCLUSIONS
CE-MS analysis of urine enabled identification of peptides as potential surrogate markers for renoprotection in microalbuminuric type 2 diabetic patients, which show persistent improvement after longterm treatment with Irbesartan. The results suggest that a major benefit of treatment by Irbesartan may be improvement of collagen turnover, reduction of fibrosis. They further suggest that urinary proteome analysis could be utilized to assess potential benefit of therapeutic intervention, providing statistically significant results even on a small population.
Steno Diabetes Centre, Gentofte, Denmark.
Sten
S
Andersen
Harald
H
Mischak
Petra
P
Zürbig
Hans-Henrik
HH
Parving
Peter
P
Rossing
D000419:Albuminuria / Q000188:drug therapy* / Q000209:etiology* / Q000652:urine; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000652:urine; D003928:Diabetic Nephropathies / Q000209:etiology / Q000517:prevention & control; D019075:Electrophoresis, Capillary; D006801:Humans; D000077405:Irbesartan; D013058:Mass Spectrometry; D020543:Proteome / Q000032:analysis* / Q000187:drug effects / Q000378:metabolism; D018709:Statistics, Nonparametric; D013777:Tetrazoles / Q000627:therapeutic use*; D016482:Urinalysis
D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D020543:Proteome; D013777:Tetrazoles; D000077405:Irbesartan